Payment overview · 2025
General Payments
$1,048.77
59 reported records · 13 companies
Healthcare provider profile · identity verified
Cory Adam Waldman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BEVERLY HILLS, CA · NPI 1740445774
Verified facts
What the public records show
CMS Open Payments records show Cory Adam Waldman, M.D. received $1,048.77 in general payments during 2025 across 59 reported records.
Amgen Inc. accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $182.90 | 17.4% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $157.07 | 15.0% | 22 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $154.10 | 14.7% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.15 | 8.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $74.95 | 7.2% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $74.65 | 7.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.53 | 7.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.22 | 5.3% | 2 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $48.75 | 4.7% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $42.71 | 4.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.70 | 4.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.17 | 3.4% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $22.87 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,048.77 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $182.90 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $154.10 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $142.08 | 21 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $133.04 | 20 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $84.15 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $84.15 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $74.95 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.22 | 2 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $48.75 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.38 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $46.05 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $42.71 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.45 | 3 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $28.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $9.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 240 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
260 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
240 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
80 | 73 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 702 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 534 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 69 |
| Synthroid | Levothyroxine Sodium | 260 | 51 |
| Eliquis | Apixaban | 240 | 40 |
| Lorazepam | Lorazepam | 226 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 218 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 43 |
| Losartan Potassium | Losartan Potassium | 205 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 48 |
| Trazodone Hcl | Trazodone Hcl | 163 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 26 |
| Metformin Hcl | Metformin Hcl | 134 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 31 |
| Alprazolam | Alprazolam | 124 | 35 |
| Furosemide | Furosemide | 118 | 34 |
| Gabapentin | Gabapentin | 117 | 22 |
| Allopurinol | Allopurinol | 107 | 26 |
| Repatha Sureclick | Evolocumab | 106 | 17 |
| Simvastatin | Simvastatin | 105 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 25 |
| Azithromycin | Azithromycin | 103 | 87 |
| Ezetimibe | Ezetimibe | 101 | 26 |
| Paxlovid | Nirmatrelvir/Ritonavir | 80 | 73 |
| Sertraline Hcl | Sertraline Hcl | 75 | 17 |
| Tramadol Hcl | Tramadol Hcl | 75 | 18 |
| Atenolol | Atenolol | 70 | 21 |
| Irbesartan | Irbesartan | 70 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 17 |
| Propranolol Hcl | Propranolol Hcl | 67 | 16 |
| Mirtazapine | Mirtazapine | 66 | 12 |
| Famotidine | Famotidine | 64 | 16 |
| Telmisartan | Telmisartan | 62 | 15 |
| Celecoxib | Celecoxib | 59 | 11 |
| Lisinopril | Lisinopril | 59 | 17 |
| Bupropion Xl | Bupropion Hcl | 58 | suppressed |
| Clonazepam | Clonazepam | 58 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 57 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 14 |
| Temazepam | Temazepam | 56 | suppressed |
| Diazepam | Diazepam | 54 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 11 |
| Mounjaro | Tirzepatide | 53 | 11 |
| Omeprazole | Omeprazole | 53 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Carvedilol | Carvedilol | 51 | 11 |
| Ozempic | Semaglutide | 51 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 51 | 15 |
| Eszopiclone | Eszopiclone | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 28 |
| Meloxicam | Meloxicam | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Livalo | Pitavastatin Calcium | 39 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 23 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 22 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Valsartan | Valsartan | 30 | 13 |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Repatha Syringe | Evolocumab | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Restasis | Cyclosporine | 21 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Zaleplon | Zaleplon | 20 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Prednisone | Prednisone | 18 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Demeclocycline Hcl | Demeclocycline Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Droxidopa | Droxidopa | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Edarbi | Azilsartan Medoxomil | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Repatha Pushtronex | Evolocumab | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,048.77 · 59 records | Amgen Inc. | Cologuard Collection Kit, ELIQUIS, EVOQUE, FFRct, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, Quviviq, RELISTOR, REPATHA, SAPIEN 3 Ultra RESILIA, UBRELVY, Wegovy, Xelstrym, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error